HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trudeau’s fine increased

This article was originally published in The Tan Sheet

Executive Summary

The U.S. District Court for the Northern District of Illinois orders infomercial marketer Kevin Trudeau to pay $37 million for violating a 2004 ban from producing or publishing infomercials by misrepresenting the contents of his book "The Weight Loss Cure 'They' Don't Want You to Know About." A judge raised the fine from more than $5 million to the amount consumers paid in response to Trudeau's deceptive infomercials, the Federal Trade Commission announces Jan. 15. The judge also expanded the three-year ban to prohibit Trudeau from disseminating or assisting to with infomercials (1"The Tan Sheet" March 28, 2005, p. 14)

You may also be interested in...



Supplement Marketer Trudeau Files False Advertising Suit Against FTC

Coral calcium marketer Kevin Trudeau is attempting to bar FTC from continuing to post a statement announcing a settlement of infomercial product claims litigation

Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials

Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.

Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Topics

UsernamePublicRestriction

Register

RS136638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel